Heterogeneity Underlies the Emergence of EGFRT790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor

RT @NicoleKuderer: This reports half of T790M-positive EGFR-mutant #lcsm treated with rociletinib are T790–wild-type upon progression, sugg…

This reports half of T790M-positive EGFR-mutant #lcsm treated with rociletinib are T790–wild-type upon progression, suggesting that T790–wild-type clones can emerge as the dominant source of resistance. Plasma ctDNA can sometimes predict emerging resistanc

RT @AACR: Celebrating Cancer Discovery’s new 24.373 Impact Factor! Read one of the journal’s highly-cited articles: https://t.co/6bZC86dBO5

RT @AACR: Celebrating Cancer Discovery’s new 24.373 Impact Factor! Read one of the journal’s highly-cited articles: https://t.co/6bZC86dBO5